Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

1. Harousseau, J.-L.
2. Palumbo, A.
3. Richardson, P.G.
4. Schlag, R.
5. Dimopoulos, M.A.
6. Shpilberg, O.
7. Kropff, M.
8. Kentos, A.
9. Cavo, M.
10. Golenkov, A.
11. Komarnicki, M.
12. Mateos, M.-V.
13. Esseltine, D.-L.
14. Cakana, A.
15. Liu, K.
16. Deraedt, W.
17. Van De Velde, H.
18. San Miguel, J.F.